On 9/20/24, OncoCyte Corp (NASDAQ: OCX) stock enjoyed a major increase of 11.3%, closing at $3.34. Moreover, trading volume in this advance was exceptionally high at 383% of normal. The stock has performed in line with the market over the last nine months and has risen 7.7% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, OCX is expected to continue to be a modest Value Eraser.
OncoCyte has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. OncoCyte has a neutral Power Rating of 47 but a poor Appreciation Score of 16, with the Negative Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment